Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 1448

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 12
Chunk 1448
---
    $2.23  
     8.6  
    $120,886 

Key
assumptions used to value stock options during the year ended December 31, 2024 are as follows:

Schedule of Key Assumptions Used to Value Stock Options

    Expected
    volatility 
     58.46-152.45% 
  
    Risk-free
    interest rate 
     3.49-4.56% 
  
    Exercise Price 
     $
                                            0.71 - $1.57 
  
    Expected
    term (years) 
     5-5.5
                                            years 
  
    Dividend
    yield 
     - 

During
the year ended December 31, 2024, a total of 500,000 restricted stock units (“RSU”), with an aggregate fair market value
of approximately $0.6 million were granted to the Company’s Chief Executive Officer under the 2022 Omnibus Incentive Plan. These
RSU’s vest as follows: (i) 50% on February 12, 2025 (ii) 50% at 6-month anniversary of date of grant. The awards were fair valued
using the closing price of the stock of $1.19 on December 6th, 2024.

As
of December 31, 2024, there was approximately $0.5 million unrecognized compensation cost related to unvested RSU’s awards granted.
These costs will be expensed in 2025.

    F-18

MIRA PHARMACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

DECEMBER 31, 2024 AND 2023

The
following is RSU activity during the year ended December 31, 2024:

 Schedule
of Restricted Stock Unit Activity

    Number
    of Restricted Shares 

    Outstanding
    as December 31, 2023 
     - 

    RSU’s
    granted 
     500,000 

    Expired 
     - 

    Forfeitures 
     - 

    Outstanding
    as December 31, 2024 
     500,000 

Warrants

In
connection with various transactions and the IPO summarized below, the Company issue stock warrants. Warrant activity for the year ended
December 31, 2024 is summarized below:

SCHEDULE